Franco Aristotle G. Larcina is a member of the firm’s Special Projects, and Banking, Finance and Securities departments. He specializes in investments, mergers and acquisitions, particularly in industries with FDI and nationality restrictions and in listed and public corporations. He has expertise in merger and competition law, securities regulations, and telecommunications, media, and technology and data privacy.
Mr. Larcina has advised clients from a wide range of industries on various competition law issues, such as the merger notifiability of their proposed acquisitions and joint ventures, and review of distribution, licensing and non-compete agreements. He has helped clients design and implement antitrust audit and compliance programs. He has also acted has competition counsel in relation to merger filings with the Philippine Competition Commission, including in relation to Sanofi’s acquisition of the consumer health care business of Boehringer Ingelheim, which received the first merger approval under the implementing rules and regulations of the Philippine Competition Act; and in relation to Alipay Singapore Holding Pte. Ltd’s acquisition of a significant minority stake in Globe Fintech Innovations, Inc., the first transaction that went through, and was unconditionally approved after, a Phase 2 Review.
He also regularly advises clients in various industries on proposed mergers, acquisitions and joint ventures, and has assisted in the conduct of several tender offers for listed and public companies. He was involved in the 2014 Php3.7 billion investment of GIC Special Investments, Ltd. (through an affiliate) in a minority stake in the Hospital Group of Metro Pacific Investments Corporation (MPIC). GIC also subscribed to an exchangeable bond issued by MPIC with a value of P6.5 billion. GIC is the global investments firm that manages the foreign reserves of Singapore. The deal was nominated as an M&A Deal of the Year in the ALB SE Asia Law Awards 2015.